Literature DB >> 15755311

Evaluation of a drug-drug interaction alert structure through the retrospective analysis of statins-macrolides co-prescriptions.

Tomas Morera1, Guillermo Gervasini, Juan Antonio Carrillo, Julio Benitez.   

Abstract

The aim of this work was the evaluation of the existent drug interaction alert structure in Spain, which is based on yellow cards notifications and circulation of drug alert letters, through the retrospective analysis of CYP3A-metabolized statins and macrolides co-prescriptions in the Spanish province of Badajoz between May and September 2001. The period of study was planned to include the release of 2 drug alert letters released by the Spanish Drug Agency in June and July, addressed to all healthcare professionals, which warned against the concomitant prescription of statins and inhibitors of their metabolism, e.g. macrolides antibacterials. 4,600,764 prescriptions were examined, 664 of which corresponded to combinations of statins and macrolides. Although a decrease was detected in the number of these co-prescriptions throughout the study, 80 of these corresponding to 67 patients were still being prescribed in September, after the warnings by the Spanish Drug Agency had been released. 431 physicians prescribed these drugs simultaneously, with 22.9% of them having more than one patient at potential risk. Doctors working at rural healthcare centres or not directly attached to any healthcare facility were more prone to prescribe unsafe coprescriptions than those working at urban health centre. This study shows that the present drug alert system is not fully efficient when facing a situation like the one retrospectively reviewed in this study, in which a prompt action, in this case termination of potentially hazardous coprescriptions, was required. New systems developed to improve prescribing, including a new method based on personal contact between Drug Surveillance Centres and general practitioners, are discussed.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15755311     DOI: 10.1111/j.1742-7843.2005.pto960403.x

Source DB:  PubMed          Journal:  Basic Clin Pharmacol Toxicol        ISSN: 1742-7835            Impact factor:   4.080


  3 in total

Review 1.  Impact of safety-related regulatory action on clinical practice: a systematic review.

Authors:  Sigrid Piening; Flora M Haaijer-Ruskamp; Jonie T N de Vries; Menno E van der Elst; Pieter A de Graeff; Sabine M J M Straus; Peter G M Mol
Journal:  Drug Saf       Date:  2012-05-01       Impact factor: 5.606

2.  The Impact of US FDA and Health Canada Warnings Related to the Safety of High-dose Simvastatin.

Authors:  Kanika Anand; Ingrid Sketris; Ying Zhang; Adrian Levy; John-Michael Gamble
Journal:  Drugs Real World Outcomes       Date:  2017-12

3.  Potential drug-drug interactions in prescriptions to patients over 45 years of age in primary care, southern Brazil.

Authors:  Jorge Juarez Vieira Teixeira; Márcia Terezinha Lonardoni Crozatti; Carlos Aparecido dos Santos; Nicolina Silvana Romano-Lieber
Journal:  PLoS One       Date:  2012-10-10       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.